Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be ...

Merck announced the $9.2 billion deal with Cidara on Friday, sending Cidara’s stock soaring 106% in recent morning trading, ...

Ruvidar and Rutherrin show strong potential in treating bladder cancer, solid tumors, and HSV-1—including drug-resistant ...

Merck agreed to pay $9.2 billion to purchase Cidara Therapeutics, looking to cash in on the firm's experimental flu treatment.

MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a preventive antibody-based therapy for influenza.

mRNA vaccines can enhance immunotherapy efficacy by activating the immune system, improving outcomes in hard-to-treat tumors. mRNA COVID-19 vaccines enhance immune responses, improving cancer ...

Amana Care Clinic in Muscatine is expanding its cough, cold, and flu treatment. The clinic offers faster diagnostic testing, ...

Merck ( MRK) to acquire Cidara Therapeutics ( CDTX) for $221.50 per share in cash, for a total transaction value of ...

RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today congratulated its former client, Cidara Therapeutics, on its acquisition by ...

According to BBC reporting, experts in the U.K. predict the country will have a severe flu season, too, based on an early ...

Merck & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker's respiratory portfolio and pipeline as it braces for the looming loss ...